<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624351</url>
  </required_header>
  <id_info>
    <org_study_id>SL0007</org_study_id>
    <secondary_id>2007-002566-35</secondary_id>
    <nct_id>NCT00624351</nct_id>
  </id_info>
  <brief_title>Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease</brief_title>
  <official_title>A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the dose response and the dose frequency of
      epratuzumab in patients with SLE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response at Week 12 according to a combined response index</measure>
    <time_frame>Week 12</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at Week 4 according to a combined response index</measure>
    <time_frame>Week 4</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 8 according to a combined response index</measure>
    <time_frame>Week 8</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 4 according to a combined response index involving Short Form-36 (SF-36) response</measure>
    <time_frame>Week 4</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, treatment failure status, and SF-36 response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 8 according to a combined response index involving Short Form-36 (SF-36) response</measure>
    <time_frame>Week 8</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, treatment failure status, and SF-36 response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 12 according to a combined response index involving Short Form-36 (SF-36) response</measure>
    <time_frame>Week 12</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, treatment failure status, and SF-36 response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement (yes/no) in British Isles Lupus Assessment Group (BILAG) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement (yes/no) in British Isles Lupus Assessment Group (BILAG) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement (yes/no) in British Isles Lupus Assessment Group (BILAG) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in British Isles Lupus Assessment Group (BILAG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total British Isles Lupus Assessment Group (BILAG) score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physician global assessment at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) response at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>SF-36 response is defined as no changes from baseline more negative than -0.8 in PCS or &gt; -2.5 changes in any of the 8 domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) response at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>SF-36 response is defined as no changes from baseline more negative than -0.8 in PCS or &gt; -2.5 changes in any of the 8 domain scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) response at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>SF-36 response is defined as no changes from baseline more negative than -0.8 in PCS or &gt; -2.5 changes in any of the 8 domain scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) response at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 response is defined as no changes from baseline more negative than -0.8 in PCS or &gt; -2.5 changes in any of the 8 domain scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life-5 Dimensions (EQ-5D) score at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first sustained British Isles Lupus Assessment Group (BILAG) response</measure>
    <time_frame>From Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to enhanced British Isles Lupus Assessment Group (BILAG) response</measure>
    <time_frame>From Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure up to Week 12</measure>
    <time_frame>From Baseline to Week 12</time_frame>
    <description>Treatment failure is defined as increase in (or addition of a new) immunosuppressive agent over baseline treatment levels, or any increase in corticosteroid baseline treatment level, or any IV, IA, or IM injections of corticosteroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative steroid dose at Week 12</measure>
    <time_frame>From Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human anti-human antibodies (HAHA) levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in levels of circulating B cells at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in levels of circulating T cells at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMAB 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMAB 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMAB 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMAB 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMAB 1800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.</description>
    <arm_group_label>EMAB 600mg</arm_group_label>
    <arm_group_label>EMAB 100mg</arm_group_label>
    <arm_group_label>EMAB 400mg</arm_group_label>
    <arm_group_label>EMAB 1200mg</arm_group_label>
    <arm_group_label>EMAB 1800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate-buffered Saline (PBS) infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>EMAB 100mg</arm_group_label>
    <arm_group_label>EMAB 400mg</arm_group_label>
    <arm_group_label>EMAB 1200mg</arm_group_label>
    <arm_group_label>EMAB 1800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive ANA result at visit 1

          -  Current diagnosis of systemic lupus erythematosus (SLE) by American College of
             Rheumatology revised criteria such that at least 4 of the 11 criteria are met

          -  Active moderate or severe SLE disease activity as demonstrated by British Isles Lupus
             Assessment Group (BILAG) A level disease activity in at least one body/organ system or
             BILAG B level disease activity in at least two body/organ systems if no BILAG A level
             disease is present

          -  If on antimalarials, dose regimen must be stable for 4 weeks prior to study entry.

        Exclusion Criteria:

          -  Patients receiving any live vaccination within 2 weeks prior to visit 1 or during the
             course of the study

          -  Active severe SLE disease activity which involves the central nervous system (CNS)
             (defined by BILAG neurologic A level activity) including transverse myelitis,
             psychosis and seizures

          -  Active severe SLE disease activity which involves the Renal system (defined by BILAG
             renal level A activity or Grade III or higher World Health Organization (WHO)
             nephritis) or serum creatinine &gt;2.5mg/dL or clinically significant serum creatinine
             increase within the prior 4 weeks or proteinuria &gt;3.5gm/day

          -  Patients with a history of anti-phospholipid antibody syndrome AND use of oral
             anticoagulants or anti-platelet treatment

          -  Patients with a history of chronic infection, recent significant infection, or any
             current sign of symptom that may indicate an infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manipal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pozna≈Ñ</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <disposition_first_submitted>November 22, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 22, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2010</disposition_first_posted>
  <last_update_submitted>September 2, 2011</last_update_submitted>
  <last_update_submitted_qc>September 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>B-Cell immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

